New Risk • Jun 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.7x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Market cap is less than US$100m (ج.م4.32b market cap, or US$82.7m). Board Change • May 20
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). MD & Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. 공시 • Apr 06
October Pharma S.A.E, Annual General Meeting, Apr 27, 2026 October Pharma S.A.E, Annual General Meeting, Apr 27, 2026, at 15:30 Egypt Standard Time. Location: cairo Egypt Board Change • May 14
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. 공시 • May 13
October Pharma S.A.E, Annual General Meeting, May 31, 2025 October Pharma S.A.E, Annual General Meeting, May 31, 2025, at 12:00 Egypt Standard Time. Location: cairo Egypt Reported Earnings • Nov 16
Third quarter 2024 earnings released: EPS: ج.م2.67 (vs ج.م4.09 in 3Q 2023) Third quarter 2024 results: EPS: ج.م2.67 (down from ج.م4.09 in 3Q 2023). Revenue: ج.م326.1m (up 24% from 3Q 2023). Net income: ج.م32.0m (down 35% from 3Q 2023). Profit margin: 9.8% (down from 19% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Sep 17
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 2.7% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (2.7% operating cash flow to total debt). Minor Risks Profit margins are more than 30% lower than last year (9.9% net profit margin). Market cap is less than US$100m (ج.م1.41b market cap, or US$29.1m). Valuation Update With 7 Day Price Move • Sep 17
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ج.م117, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 124% over the past three years. Reported Earnings • May 30
First quarter 2024 earnings released: EPS: ج.م3.52 (vs ج.م2.94 in 1Q 2023) First quarter 2024 results: EPS: ج.م3.52 (up from ج.م2.94 in 1Q 2023). Revenue: ج.م274.4m (up 29% from 1Q 2023). Net income: ج.م50.1m (up 42% from 1Q 2023). Profit margin: 18% (up from 17% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • May 21
Upcoming dividend of ج.م2.50 per share Eligible shareholders must have bought the stock before 28 May 2024. Payment date: 30 May 2024. The company last paid an ordinary dividend in April 2017. The average dividend yield among industry peers is 3.3%. Reported Earnings • Mar 16
Full year 2023 earnings released: EPS: ج.م12.53 (vs ج.م9.48 in FY 2022) Full year 2023 results: EPS: ج.م12.53 (up from ج.م9.48 in FY 2022). Revenue: ج.م1.01b (up 39% from FY 2022). Net income: ج.م182.1m (up 39% from FY 2022). Profit margin: 18% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Oct 01
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (ج.م1.20b market cap, or US$38.8m). Valuation Update With 7 Day Price Move • Dec 21
Investor sentiment improved over the past week After last week's 19% share price gain to ج.م95.30, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 210% over the past three years. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 9 non-independent directors. Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 9 non-independent directors. Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Upcoming Dividend • Apr 13
Upcoming dividend of ج.م4.00 per share Eligible shareholders must have bought the stock before 20 April 2022. Payment date: 26 April 2022. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.0%). Reported Earnings • Jun 19
First quarter 2021 earnings released The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ج.م165.8m (up 38% from 1Q 2020). Net income: ج.م40.6m (up 402% from 1Q 2020). Profit margin: 25% (up from 6.7% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Jun 02
Inaugural dividend of ج.م3.00 per share Eligible shareholders must have bought the stock before 09 June 2021. Payment date: 13 June 2021. The company last paid an ordinary dividend in May 2018. The average dividend yield among industry peers is 4.2%.